As a matter of fact, a neutralizing antibody against human CCN2 was developed and subjected to clinical trials for the treatment of idiopathic pulmonary fibrosis [146], muscular dystrophy [121], diabetes [147] and locally advanced pancreatic cancer cases [148]. Here, CCN2 is linked to idiopathic pulmonary fibrosis.